ANI Pharmaceuticals, Inc. cash flow to debt ratio of 56.96% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

ANI Pharmaceuticals, Inc.'s free cash flow has increased 220.64% from $47.06M last year to $150.90M, signaling increasing performance

ANI Pharmaceuticals, Inc.'s debt to equity ratio is 0.58, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

ANI Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 1.46 last year to 0.58 today, signaling strengthened financials

ANI Pharmaceuticals, Inc. has a net debt to EBITDA ratio of 0.19x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

ANI Pharmaceuticals, Inc.'s interest coverage ratio of 3.86 indicates that earnings with good margin can cover interest payments on company debt

ANI Pharmaceuticals, Inc.'s profit margin has increased (-421.99%) in the last year from -3.01% to 9.71%, signaling increasing performance

ANI Pharmaceuticals, Inc.'s short-term assets of $753.12M exceed its short-term liabilities of $278.11M

ANI Pharmaceuticals, Inc.'s return on assets of 6.31% is higher than the 5.00% threshold, indicating efficient asset utilization

ANI Pharmaceuticals, Inc.'s return on equity of 17.32%, is higher than 15.00%, indicating good performance

ANI Pharmaceuticals, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

ANI Pharmaceuticals, Inc. had positive net income in only 2.00 out of 5 years, indicating unstable earnings

ANI Pharmaceuticals, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

ANI Pharmaceuticals, Inc. has a free cash flow yield of 7.86%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

ANI Pharmaceuticals, Inc.'s yearly earnings has increased -522.94% since last year from $-18.52M to $78.34M, signaling increasing performance

ANI Pharmaceuticals, Inc.'s yearly revenue has increased 43.78% since last year from $614.38M to $883.37M, signaling increasing performance

ROIC 8.17% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

ANI Pharmaceuticals, Inc.'s 3-year revenue CAGR of 40.81% is positive, indicating growing revenue over the past 3 years

ANI Pharmaceuticals, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

ANI Pharmaceuticals, Inc. had positive ROE in only 2.00 out of 5 years, indicating inconsistent returns on equity

ANI Pharmaceuticals, Inc. has insufficient data to evaluate this check.

ANI Pharmaceuticals, Inc. has an earnings yield of 5.07%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

ANI Pharmaceuticals, Inc. is overvalued relative to its fair value price of 62.97 based on EBITDA multiple model

ANI Pharmaceuticals, Inc. has an EV/EBITDA ratio of 8.26x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

ANI Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.95 based on Earnings Fair Value model

ANI Pharmaceuticals, Inc. has a PEG-ratio under 1 which is considered undervalued

ANI Pharmaceuticals, Inc. has a price-to-book ratio of 3.14x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

ANI Pharmaceuticals, Inc. has a price-to-sales ratio of 2.08x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue